bivalirudin and Budd-Chiari-Syndrome

bivalirudin has been researched along with Budd-Chiari-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for bivalirudin and Budd-Chiari-Syndrome

ArticleYear
Budd-Chiari syndrome in very young adult patients with polycythemia vera: report of case series with good outcome with direct thrombin inhibitor treatment.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:8

    Polycythemia vera is a Philadelphia chromosome-negative myeloproliferative disorder with incidence of 1% under the age of 25. The Budd-Chiari syndrome (BCS) is a well known complication of polycythemia vera even in children, and characterized by occlusion of hepatic outflow. A computerized archive search of medical records at Sheba Medical Center of the past three decades of patients with polycythemia vera and BCS under the age of 25 years was performed. A work-up for JAK2 V617F mutation and thrombophilia was done. Medical charts and imaging tests were carefully reviewed. Three patients under the age of 22 were finally recruited. Two of those were found in life-threatening condition and improved clinically following treatment with bivalirudin, a direct thrombin inhibitor. It is conceivable that bivalirudin contributed to a favorable outcome of those patients in comparison to historical outcome previously reported. In conclusion, polycythemia vera in the young is not a mild disease since BCS, which is one of its complication, can be fatal even in those age group unrelated to the presence of hereditary thrombophilia. Once BCS occurs, we would suggest giving a trial with bivalirudin before an invasive procedure is planned.

    Topics: Adolescent; Antithrombins; Budd-Chiari Syndrome; Child; Female; Hirudins; Humans; Janus Kinase 2; Liver; Male; Mutation; Peptide Fragments; Polycythemia Vera; Recombinant Proteins; Thrombin; Thrombophilia; Treatment Outcome; Young Adult

2013
Use of bivalirudin to prevent thrombosis following orthotopic liver transplantation in a patient with Budd-Chiari syndrome and a history of heparin-induced thrombocytopenia.
    Annals of clinical and laboratory science, 2008,Summer, Volume: 38, Issue:3

    Type II heparin-induced thrombocytopenia (HIT) is an immune-mediated syndrome that may arise in a time-dependent manner following heparin therapy, placing patients at significant risk for thromboembolic events. Therapy includes anticoagulation with a direct thrombin inhibitor and avoidance of heparin. We report a patient with Budd-Chiari syndrome and a history of heparin-induced thrombocytopenia who presented for orthotopic liver transplant and required postoperative anticoagulation with bivalirudin. During the post-transplant graft function improvement, we observed a significant dose-effect alteration manifested by an increased bivalirudin dose requirement as factor V activity increased. This observation is an important consideration in the attempt to maintain an optimal balance between effective anticoagulation and a reduced risk of postoperative bleeding.

    Topics: Adult; Anticoagulants; Blood Coagulation; Budd-Chiari Syndrome; Dose-Response Relationship, Drug; Factor V; Heparin; Hirudins; Humans; Liver; Liver Transplantation; Male; Partial Thromboplastin Time; Peptide Fragments; Recombinant Proteins; Thrombocytopenia; Thrombosis

2008